Sanofi SA SNY reported a 1% decline in Q2 business operating income of €2.73 billion. Business EPS of €1.74, up 0.6% on a reported basis and 8.1% at CER.
Revenues increased €9.96 billion, down 1.5% and up 3.3% at constant currency.
Specialty Care grew 11.8% to €4.4 billion, driven by Dupixent (€2.56 billion, +34.2%) and Nexviazyme (€103 million, +146.5%), more than offsetting the anticipated impact of Aubagio generic competition in the U.S.
Vaccines sales were up 9.1% Y/Y to €1.22 billion, mainly driven by Polio/Pertussis/Hib (PPH).
General Medicines sales decreased 12.8% Y/Y €3.11 billion (down 7.3% on constant currency). Core assets were down 2.9% to €1.56 billion (up 2.4% on constant currency).
Non-core assets were lower mainly due to Lantus (€353 million, -41.2%).
Consumer healthcare sales growth continued (+0.7% on constant currency) despite unfavorable effect from inventory build in the prior quarter.
Outlook: Sanofi increased its FY23 Business EPS guidance to grow mid-single-digit at CER, citing strong sales from new drug launches, excluding the effect of currency swings. The negative currency impact on 2023 earnings is expected to be 6.5%-7.5%.
It had previously expected 2023 adjusted EPS to grow by a "low single-digit" percentage, with an additional negative currency impact of 5.5%-6.5%.
The improved outlook also includes about €400 million of expected one-off COVID-19 vaccine revenues in the second half of the year, with no further sales expected after that.
Price Action: SNY shares are down 2.13% at $52.40 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.